Our objective is to assess the effect of genetic and environmental factors on Crohn's disease location.
C
rohn's disease (CD) is a chronic relapsing inflammatory intestinal disorder that can affect any segment of the intestine, often in a discontinuous manner. 1, 2 Because CD is phenotypically heterogeneous, CD patients are further stratified on the basis of 3 parameters: 1) age at diagnosis, 2) disease location, and 3) disease behavior based on the Vienna and Montreal classification systems. 3, 4 Although the first 2 parameters are stable over time, disease behavior is dynamic and therefore difficult to correlate with genotype data. 5 Four major patterns of disease location have been defined: L1, ileal disease with or without cecal disease ("pure" ileal CD); L2, colonic disease only (Crohn's colitis); L3, ileal disease with colonic disease beyond the cecum (ileocolonic disease); and L4, proximal intestinal disease. Approximately 70% to 85% of CD patients have ileal disease involvement (L1 ϩ L3), and 15% to 30% have colonic disease (L2) without ileal involvement. 6 -8 Only a very small number of patients have disease restricted to the proximal gut (L4).
Both genetic factors and environmental factors have been associated with ileal disease location (L1 ϩ L3). Smoking has been linked to small-bowel as opposed to colonic disease. 9 -12 NOD2 and ATG16L1 risk alleles have been associated with ileal disease location based on comparisons of the ileal CD subset with control patients considering only a limited number of genetic loci. [13] [14] [15] [16] [17] [18] [19] Since then, more than 30 CD susceptibility loci have been identified through genome-wide association studies. 20 Taking these susceptibility loci and smoking into consideration, we have conducted logistic regression analysis on a single CD database to assess genetic and environmental factors that are differentially associated with the ileal CD subset L1 ϩ L3, compared with the colonic CD subset without ileal disease (L2).
MATERIALS AND METHODS

Subjects
This study was approved by the Washington University and Stony Brook University Institutional Review Boards. We identified 628 CD subjects from the Washington University Digestive Diseases Research Core Center Tissue Procurement Facility database (April 2005 through February 2010) that had complete clinical information on Montreal disease location, smoking status, sex, race, age at diagnosis, and complete genotype information on 31 established CD genetic susceptibility loci. Subjects were recruited to the Washington University Digestive Diseases Research Core Center Tissue Procurement Facility in a consecutive fashion during inpatient and outpatient visits to physicians within the Section of Colon Rectal Surgery and the Division of Gastroenterology at the Washington University Medical Center to donate de-identified clinical information and blood, saliva, and/or tissues for genotyping. Patients who were unwilling or unable to give informed consent were excluded from the database.
Clinical Variables
Sex and race were recorded as reported by the patients (see Table 1 ). Based on a review of the subjects' medical records, they were classified into one of the following Montreal disease location categories: L1, ileal disease with or without cecal disease (ileal CD); L2, colonic disease only (Crohn's colitis); L3, ileal disease with colonic disease beyond the cecum; and L4, proximal intestinal disease. 3 The first 3 categories (L1, L2, and L3) include patients who also had proximal intestinal disease location as a modifier (L4ϩ). In patients that had undergone subtotal colectomy, L2 CD was distinguished from ulcerative colitis (UC) and indeterminate colitis based on the pathology of the resected specimen. The database includes patients initially diagnosed with UC but subsequently reclassified as CD after developing small-bowel or perianal disease. It is therefore possible that some of the UC patients in our database who were excluded from the present study may be reclassified as CD in the future. Subjects were also classified into one of the Montreal disease location categories: A1, age Ͻ17 years; A2, 17 to 40 years; A3, Ͼ40 years. 3 Because disease behavior is dynamic over time, we did not include this variable for this analysis. The patient's smoking history was determined at the time of initial surgery or the most recent follow-up before surgery by reviewing the medical records and interviewing the patient. A smoker was defined as smoking Ն7 cigarettes a week for at least a year as described previously. 5, 9, 11 An ex-smoker was defined as a subject who had stopped smoking for at least a year. A nonsmoker was defined as a subject who had never smoked any cigarettes.
Genotyping DNA was prepared from peripheral blood mononuclear cells, saliva, and/or GI tissue by use of Qiagen Gentra Puregene (Qiagen Inc., Valencia, CA) reagents according to the manufacturer's recommendations. Genotyping of the NOD2 single-nucleotide polymorphism (SNP), Leu1007fsInsC (rs2066847, SNP13), was conducted by Taqman allelic discrimination as previously described. 21 Applied Biosystems Taqman SNP Genotyping assays (catalogue nos. C_11717468 and C_11717466; Life Technologies Co., Carlsbad, CA) were used to genotype NOD2 R702W (rs2066844, SNP8) and G908R (rs2066845, SNP12) alleles, according to the manufacturer's recommendations. The remaining SNPs (see Table 2 ) were genotyped using the Sequenom MassArray System (Sequenom The distribution of genotypes is shown with respect to the 4 major disease locations. L1, L2, and L3 include subjects with L4 as a modifier. Because there were only 6 L4 patients with only L4 disease, these patients were excluded from the analysis. All values are presented as percentages. CD ϭ Crohn's disease; SNP ϭ single-nucleotide polymorphism; R ϭ risk; NR ϭ nonrisk.
Inc., San Diego, CA) in the Washington University Sequenom Technology Core.
Statistical Analysis
The 3 major NOD2 (rs2066847, rs2066844, and rs2066845) risk alleles were combined into a single "super" allele. Subjects with 2 risk alleles (either homozygote or compound heterozygote) or with a single risk allele were designated as R (risk). Those with none of the 3 risk alleles were designated as NR (nonrisk). In this analysis we present age at diagnosis as a categorical variable, based on the Montreal classification. Logistic regression was applied to model the effect on disease locations (L1 ϩ L3 vs L2) of all the CD genotypes, sex, race, smoking, and age at diagnosis. We did stepwise variable selection in SAS 9.0 to identify significantly effective SNPs or other covariates (␣ ϭ .05). All predictor variables were treated as categorical ones with 3 possible types. The likelihood-ratio test (approximately 2 test) was conducted during every round of variable selection. Afterward, we also performed the best subset selection in R (code supplied on request to authors) to confirm our findings. Akaike information criterion was set as the goodness of fit to assess subsets. We also conducted the analysis with only the SNPs.
RESULTS
The clinical characteristics of the CD patients with respect to disease location are summarized in Table 1 . The relative distribution of CD patients with ileal disease (L1 ϩ L3) and with only colonic disease (L2) in this database was approximately 80:20. Only 6 (ϳ1%) of the CD patients had isolated proximal bowel disease (L4), and these patients were not included in the subsequent analysis. The CD patients were predominantly white. The predominant categorical age at diagnosis based on Montreal classification was A2 (17-40 y). A lower proportion of L2 patients than of L1 ϩ L3 patients had undergone surgery as of the cutoff date (February 2010). The distribution of CD genotypes for 31 established CD genetic loci with respect to disease location are summarized in Table 2 . We performed logistic regression analysis by stepwise variable selection to evaluate all 31 established CD genetic loci along with the clinical covariates, including smoking, on disease site. CD patients with 2 NOD2 risk alleles (R/R, OR 6.102, 95% CI 1.855-20.074) and with one NOD2 risk allele (R/NR, OR 2.552, 95% CI 1.479 -4.402) have a 2-fold risk (OR 2.552, 95% CI 1.479 -4.402) of developing ileal (L1 ϩ L3) disease compared with pure colonic (L2) disease. Current smokers have an increased risk of developing ileal compared with colonic disease than both control (O. 1.689, 95% CI 1.071-2.664), and ex-smokers (OR 2.611, 95% CI 1.279 -5.319) of developing ileal vs isolated colonic disease (see Table 3 ). In contrast, CD patients with 1 or 2 TNFSF15 risk alleles have ϳ4-fold risk of developing isolated colonic compared with ileal disease. When the logistic regression was performed with only genotype data, NOD2 and TNFSF15 genotype were selected with similar OR and 95% CI by both stepwise variable selection and best subset selection.
DISCUSSION
This is one of the first studies to evaluate the effect of 31 established CD genetic loci with clinical covariates, including smoking, on CD site (L1 ϩ L3 vs L2) using logistic regression. 20 This study demonstrates that both NOD2 risk alleles and smoking were associated with an increased risk of developing ileal disease vs isolated colonic disease. It thus confirms the results of a previous logistic regression study that examined NOD2 risk alleles alone with other clinical covariates including smoking, and other studies that have examined these 2 variables separately. 9 -15,22,23 Waterman et al 24 recently reported the allelic frequencies of 31 established genetic loci and 6 additional UC loci in 366 L1 compared with 228 L2 CD patients. Two NOD2 loci (rs2066844, 0.1014 vs 0.05, P ϭ .002; rs2066847, 0.1113 vs 0.0376, P ϭ .0001), the ATG16L1 locus (rs2241880, 0.381 vs 0.455, P ϭ .024) and the ICOSL1 locus (rs762421, 0.4345 vs 0.3484, P ϭ .0131) demonstrated significantly different allelic frequencies in univariate analyses, and did not include smoking as a covariate in the analysis. Our study demonstrates that current smoking has a tremendous impact on disease location in CD, and it suggests that analysis of additional genetic and environmental factors should include smoking as a covariate. In this study smoking history was elicited by patient report alone. Measurement of serum cotinine levels may provide a more objective indicator of active smoking in future studies. 25 In addition, logistic regression analysis identified the TNSF15 (rs4263839) genotype as significantly associated with a reduced risk of developing ileal disease (L1 ϩ L3) vs isolated colonic disease (L2). This particular SNP was chosen because it was the same SNP as assayed previously by Barrett et al. 20 TNFSF15 SNPs have been previously associated with CD and, in certain populations, with UC. 26 -30 The causative TNFSF15 SNP has not been identified thus far despite extensive sequencing of the gene. It is possible that this SNP is in linkage equilibrium, or nonrandomly associated, with the true disease allele, which may or may not affect TNFSF15 expression.
The ATG16L1T300A GG genotype has been associated with ileal CD compared with control patients. 16 -19 We were unable to detect an effect of ATG16L1 genotype when comparing ileal CD with isolated colonic disease. It is noteworthy that a recent meta-analysis found excessive odds ratio heterogeneity among previous studies comparing the distribution of ATG16l1 risk allele frequency in ileal compared with colonic disease. 18 It is interesting to note that the allelic frequency of the ATG16L1 risk allele was actually higher in the L2 CD patients than in the L1 CD patients in the study reported by Waterman et al. 24 Because smoking is self-reported, the classification of smoking status is not as robust as the genotyping data. The ability to detect disease site associations in this singlecenter study may be limited by the population size, low allelic frequency, and/or a low OR of certain CD risk alleles. We anticipate that more SNPs will emerge in meta-analyses combining datasets from multiple centers. Nonetheless, this study reinforces the concept that isolated Crohn's colitis exhibits molecular characteristics that are distinct from those of the 2 other major CD subtypes, ileal (L1) and ileocolonic (L3) CD. 22 
